CONTEXT: Intensive treatments intended to sustain life are often used for patients with advanced cystic fibrosis (CF). There are no guidelines for selecting patients whose survival and quality of life may be enhanced by such treatments or for communication with patients and caregivers about possible treatment outcomes. OBJECTIVES: We aimed to describe caregivers' perspectives on decision making for the use of intensive treatments for patients with advanced CF lung disease. METHODS: We conducted semi-structured interviews with 36 caregivers of 36 patients who died of CF about treatment preference discussions and solicited recommendations for improving discussions. RESULTS: Twenty (56%) patients received intensive treatments during the last week of life. Twenty-two (61%) caregivers reported ever having discussed intensive treatment preferences with a physician, and 17 (77%) of these discussions were initiated during an acute illness. Only 14 (39%) of all patients participated. Caregivers expressed less certainty about consistency of treatments with patient preferences when patients did not participate. Twenty-nine (81%) caregivers endorsed first discussing treatment preferences during a period of medical stability. CONCLUSIONS: Discussions about preferences for the use of intensive treatments for patients with CF often take place during episodes of acute illness and may be delayed until patients themselves are too ill to participate. Bereaved caregivers suggest first addressing intensive treatment preferences during a stable period so that patient preferences are understood and unwanted treatments are minimized.
CONTEXT: Intensive treatments intended to sustain life are often used for patients with advanced cystic fibrosis (CF). There are no guidelines for selecting patients whose survival and quality of life may be enhanced by such treatments or for communication with patients and caregivers about possible treatment outcomes. OBJECTIVES: We aimed to describe caregivers' perspectives on decision making for the use of intensive treatments for patients with advanced CF lung disease. METHODS: We conducted semi-structured interviews with 36 caregivers of 36 patients who died of CF about treatment preference discussions and solicited recommendations for improving discussions. RESULTS: Twenty (56%) patients received intensive treatments during the last week of life. Twenty-two (61%) caregivers reported ever having discussed intensive treatment preferences with a physician, and 17 (77%) of these discussions were initiated during an acute illness. Only 14 (39%) of all patients participated. Caregivers expressed less certainty about consistency of treatments with patient preferences when patients did not participate. Twenty-nine (81%) caregivers endorsed first discussing treatment preferences during a period of medical stability. CONCLUSIONS: Discussions about preferences for the use of intensive treatments for patients with CF often take place during episodes of acute illness and may be delayed until patients themselves are too ill to participate. Bereaved caregivers suggest first addressing intensive treatment preferences during a stable period so that patient preferences are understood and unwanted treatments are minimized.
Authors: Marie Bakitas; Tim A Ahles; Karen Skalla; Frances C Brokaw; Ira Byock; Brett Hanscom; Kathleen Doyle Lyons; Mark T Hegel Journal: Cancer Date: 2008-04-15 Impact factor: 6.860
Authors: Melissa Basile; Lincy Jojan; Mara R Hobler; Elisabeth P Dellon; Anna M Georgiopoulos; Jessica L Goggin; Elaine Chen; Christopher H Goss; Sarah E Hempstead; Albert Faro; Dio Kavalieratos Journal: J Palliat Med Date: 2021-04-20 Impact factor: 2.947
Authors: Sima Z Bedoya; Abigail Fry; Mallorie L Gordon; Maureen E Lyon; Jessica Thompkins; Karen Fasciano; Paige Malinowski; Corey Heath; Leonard Sender; Keri Zabokrtsky; Maryland Pao; Lori Wiener Journal: Front Psychol Date: 2022-06-08
Authors: Emma Beecham; Linda Oostendorp; Joanna Crocker; Paula Kelly; Andrew Dinsdale; June Hemsley; Jessica Russell; Louise Jones; Myra Bluebond-Langner Journal: Health Expect Date: 2016-09-26 Impact factor: 3.377
Authors: Dio Kavalieratos; Anna M Georgiopoulos; Lara Dhingra; Melissa J Basile; Elliot Rabinowitz; Sarah E Hempstead; Albert Faro; Elisabeth P Dellon Journal: J Palliat Med Date: 2020-09-16 Impact factor: 2.947